Evidence map›Paper›PMID 32998189›Full record

ArticleMolecules (Basel, Switzerland)2020

Effectiveness of

Adriana Patricia Tofiño-Rivera, Glorismar Castro-Amaris, Fánor Casierra-Posada

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Adriana Patricia Tofiño-RiveraCorporación Colombiana de Investigación Agropecuaria-AGROSAVIA, Research Center Motilonia, Km 5 vía a Becerril, Agustín Codazzi 202050, Colombia.ORCID 0000-0001-7115-7169
Glorismar Castro-AmarisFaculty of Health, Microbiology Program, Universidad Popular del Cesar, Research Group in Parasitology-Millennium Agroecology, Valledupar 200002, Colombia.
Fánor Casierra-PosadaFaculty of Agricultural Sciences, Research Group in Plant Ecophysiology, Universidad Pedagógica y Tecnológica de Colombia (UPTC), Tunja 150001, Colombia.ORCID 0000-0001-7508-5174
Colombian Corporation for Agricultural Research - AGROSAVIA · COPedagogical and Technological University of Colombia · COPopular University of Cesar · CO

Funding

Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS) project CT 80740-509-2019Ministerio de Agricultura y Desarrollo Rural project ID714
6 · The paper itself

Abstract

One of the principal etiological agents associated with losses in horticultural crops is the fungus

methodsThe extraction and phytochemical analysis of the EO of

resultsThe EO from the citral chemotype (58%) encapsulated in the chitosan-agar, with an 83% encapsulation efficiency in mass percentage, resulted in the total inhibition of mycelial growth at a minimum inhibitory concentration of 1370 ppm. This concentration was effective in controlling the disease under greenhouse conditions. The effectivity of the capsules containing EO was superior to that of other controls using EO evaluated in vitro. The capsules demonstrated an effective period of 51 days, with an additional 30 days of effectiveness after a reinfection cycle, thus providing similar results to the control with

conclusionsChitosan capsules present a promising strategy in the use of

Indexed as

AgarAntifungal AgentsCapsicumCapsulesChitosanColletotrichumCymbopogonDNA, IntergenicMicrobial Sensitivity TestsOils, VolatileVirulenceAgarAntifungal AgentsCapsulesChitosanDNA, IntergenicOils, Volatileanthracnosecitralencapsulationlemongrasssweet pepper

Identifiers

PMID32998189
PMCPMC7582355
OpenAlexW3088638631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.